PMID: 9536878Apr 16, 1998Paper

Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers

The British Journal of Ophthalmology
C Baudouin, C de Lunardo

Abstract

A crossover, randomised double blind study was undertaken in 30 healthy volunteers, in order to compare the tolerance of 2% carteolol with and without preservative in short term use. Complete ophthalmic examinations were performed before and 30, 60, and 180 minutes after instillation of one drop of the solution, and after 3 days of preservative treatment. After a 5 day washout, the same examinations were done with the second drug. Results showed good general tolerance for both formulations. No significant difference in subjective tolerance, corneal aesthesiometry, punctuate keratitis, Schirmer's test, intraocular pressure (IOP) decrease (about 25% in the two groups at 3 hours, 10% after 3 days of treatment), resting cardiac frequency, or blood pressure was observed. However, break up time was significantly reduced from baseline by preserved carteolol both at 3 hours (10.40 (5.9) seconds to 6.15 (3.9) seconds, p = 0.001) and after 3 days (7.72 (5.5) seconds, p = 0.04). Preservative free carteolol did not significantly change the break up time (baseline 9.08 (5.7) seconds; 3 hours = 7.88 (5.5) seconds, not significant; day 3 = 8.35 (5.8), non-significant). These results confirm that carteolol is well tolerated, either with or wit...Continue Reading

References

Aug 1, 1991·Klinische Monatsblätter für Augenheilkunde·R Marquardt, T Schubert
Nov 1, 1990·Archives of Ophthalmology·M J LavinR A Hitchings
Nov 1, 1990·Ophthalmology·T L YoungM D Farber
Dec 1, 1988·The British Journal of Ophthalmology·G R Duff, R G Newcombe
Apr 1, 1995·The British Journal of Ophthalmology·E V KuppensJ A van Best
Jan 1, 1993·Journal of Ocular Pharmacology·T J Zimmerman
Sep 1, 1994·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·H MietzG K Krieglstein
Aug 1, 1994·Klinische Monatsblätter für Augenheilkunde·N Anders, J Wollensak
Nov 1, 1994·Archives of Ophthalmology·D C BroadwayR A Hitchings
Apr 1, 1994·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·C de JongJ van Best

❮ Previous
Next ❯

Citations

Jan 11, 2002·Advances in Therapy·R Noecker
Feb 22, 2012·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Reiko AritaShiro Amano
Apr 27, 2002·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Pascal FurrerRobert Gurny
Dec 4, 2008·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Hae Y ParkChan K Park
Oct 28, 2010·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Giulia RenieriHagen Thieme
Mar 18, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Françoise Brignole-BaudouinChristophe Baudouin
Aug 3, 2013·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Manlong XuDavid J McCanna
Mar 27, 2002·The British Journal of Ophthalmology·P J PisellaC Baudouin
Mar 22, 2013·Clinical Ophthalmology·Masamichi FukudaHiroshi Sasaki
Aug 12, 2009·Clinical Ophthalmology·Michael B Horsley, Malik Y Kahook
Nov 21, 2007·Drugs & Aging·Albert S KhouriRobert D Fechtner
Sep 16, 2011·Expert Opinion on Pharmacotherapy·Marina PapadiaCarlo E Traverso
Sep 5, 2015·Drug Development and Industrial Pharmacy·Jiayu XinHongzhuo Liu
Sep 13, 2011·Expert Opinion on Drug Delivery·Maurizio RolandoMalik Y Kahook
Mar 17, 2011·Expert Opinion on Emerging Drugs·Alessandro BagnisCarlo E Traverso
Oct 14, 2014·Current Eye Research·Roberto Damian Pacheco PintoSandra Helena Alves Bonon
Jun 10, 2009·Cutaneous and Ocular Toxicology·Indu Pal KaurHarinder Singh
Mar 23, 2010·Progress in Retinal and Eye Research·Christophe BaudouinFrançoise Brignole-Baudouin
Oct 31, 2008·Acta Ophthalmologica. Supplement·John Thygesen
Sep 5, 2013·The Journal of Pharmacy and Pharmacology·Philippe DaullJean-Sébastien Garrigue
Mar 29, 2011·Annales pharmaceutiques françaises·H Chibret
Feb 16, 2010·American Journal of Ophthalmology·Saskia M MacaTalin Barisani-Asenbauer
Jan 18, 2006·Journal of Cataract and Refractive Surgery·Marianne O PriceDavid Maclellan
Oct 26, 2005·Journal of Cataract and Refractive Surgery·Ben L MasonDarlene Miller
Aug 15, 2015·International Ophthalmology·Lorena Romero-Díaz de LeónAlejandro Navas
Oct 4, 2014·Saudi Journal of Ophthalmology : Official Journal of the Saudi Ophthalmological Society·Elmer Y Tu
Oct 1, 2011·Saudi Journal of Ophthalmology : Official Journal of the Saudi Ophthalmological Society·Alessandro BagnisCarlo E Traverso

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.